Drug Profile
Research programme: deubiquitinating enzyme inhibitors - ATON/Servier
Latest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator Hybrigenics; Servier
- Developer ATON; Servier
- Class Antineoplastics; Enzymes
- Mechanism of Action Ubiquitin-specific protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer